Monogram price target raised to $10.80 from $4 at Roth Capital

Roth Capital raised the firm’s price target on Monogram Technologies (MGRM) to $10.80 from $4 and keeps a Buy rating on the shares after the company reported Q2 results a month after the previously announced acquisition of Monogram by Zimmer Biomet (ZBH) for $4.04 per share in addition to a non-tradable contingent value right. The firm is raising its price target to account for the initial cash price along with the discounted milestone payments, the analyst noted.